News
Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...
UT Dell Medical School study helps solve question of when to start blood thinners after a stroke in someone with AFib.
AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...
On CNBC's "Mad Money Lightning Round," Jim Cramer praised home improvement retailer Lowe's Companies and CrowdStrike Holdings ...
Roche is considering selling its prescription medicines in the U.S. directly to consumers to lower costs for patients as part ...
Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer reflected on. When asked about the stock during the ...
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
1d
24/7 Wall St. on MSNI Am Buying 5 Blue-Chip Dividend Stocks That Have Been Crushed in 2025
These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.
1d
24/7 Wall St. on MSN5 Stocks Yielding 6% and More You Can Buy Now and Forget About Forever
Here are five high-yield dividend stocks that offer passive income and solid entry points that investors can buy and forget ...
A direct-to-consumer program for its drugs could bring down higher U.S. drug prices while cutting out pharmacy benefit managers.
Pharmaceutical companies have been in talks with the U.S. government to figure out how to bring drug prices down after President Trump signed in May an executive order that ties U.S. prices to the ...
Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results